At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Allergen Immunotherapy Extract +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Prospective, Parallel Group Evaluation of a Novel Biologic Therapy for Perennial Allergic Rhinitis
In Brief
A Phase 2 clinical trial evaluating Allergen Immunotherapy Extract and Allergen Immunotherapy Control for Allergic Rhinitis. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of allergic rhinitis (perennial and seasonal).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedDec 2017
Primary CompletionJun 2018
Study CompletionNov 2018
TodayJul 2026
First PostedDec 2, 2017
Enrollment StartDec 19, 2016
Primary CompletionJun 1, 2018
Study CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.6 years ago
Interventions
Allergen Immunotherapy Extractdrug
Allergen Immunotherapy treatment mixture to be delivered subcutaneously
Allergen Immunotherapy Controldrug
Allergen Immunotherapy Control Solution to be delivered subcutaneously